In addition, higher Bcl2 levels in human CRC (Fig. 8F) suggest that the ability of SPARC to interfere with Bcl2's interaction with caspase 8 may be clinically relevant and can be targeted as a potential therapeutic. The gene discussed is SPARC; the disease is colorectal carcinoma.